Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 6
2010 4
2011 4
2012 3
2013 7
2014 5
2015 6
2016 8
2017 7
2018 10
2019 6
2020 10
2021 11
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

85results
Results by year
Filters applied:.Clear all
Page 1
European Respiratory Society guidelines for the management of adult bronchiectasis.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M,Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. Polverino E, et al. Among authors:ringshausen fc. Eur Respir J. 2017 Sep 9;50(3):1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep. Eur Respir J. 2017. PMID:28889110 Free article.
安全性和有效性的Elexacaftor / Tezacaftor / Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or MoreF508delAlleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS,Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Griese M, et al. Among authors:ringshausen fc. Am J Respir Crit Care Med. 2021 Feb 1;203(3):381-385. doi: 10.1164/rccm.202008-3176LE. Am J Respir Crit Care Med. 2021. PMID:32969708 Free PMC article. Clinical Trial. No abstract available.
[Evidence-based treatment of cystic fibrosis].
Ringshausen FC, Hellmuth T, Dittrich AM. Ringshausen FC, et al. Internist (Berl). 2020 Dec;61(12):1212-1229. doi: 10.1007/s00108-020-00896-9. Internist (Berl). 2020. PMID:33201261 Review. German.
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused byMycobacterium aviumComplex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ,Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Griffith DE, et al. Among authors:ringshausen fc. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC. Am J Respir Crit Care Med. 2018. PMID:30216086 Clinical Trial.
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM, Daines C,Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Rowe SM, et al. Among authors:ringshausen fc. N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3. N Engl J Med. 2017. PMID:29099333 Free PMC article. Clinical Trial.
Efficacy and safety of TOBI Podhaler inPseudomonas aeruginosa-infected bronchiectasis patients: iBEST study.
Loebinger MR, Polverino E, Chalmers JD, Tiddens HAWM, Goossens H, Tunney M,Ringshausen FC,希尔,Pathan R, Angyalosi G,布拉西F, ElbornSJ, Haworth CS; iBEST-1 Trial Team. Loebinger MR, et al. Among authors:ringshausen fc. Eur Respir J. 2021 Jan 5;57(1):2001451. doi: 10.1183/13993003.01451-2020. Print 2021 Jan. Eur Respir J. 2021. PMID:32855225 Free article. Clinical Trial.
[Management of Primary Ciliary Dyskinesia].
Raidt J, Brillault J, Brinkmann F, Jung A, Koerner-Rettberg C, Koitschev A, Linz-Keul H, Nüßlein T,Ringshausen FC, Röhmel J, Rosewich M, Werner C, Omran H. Raidt J, et al. Among authors:ringshausen fc. Pneumologie. 2020 Nov;74(11):750-765. doi: 10.1055/a-1235-1520. Epub 2020 Sep 25. Pneumologie. 2020. PMID:32977348 Free PMC article. Review. German.
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.
Aliberti S, Goeminne PC, O'Donnell AE, Aksamit TR, Al-Jahdali H, Barker AF, Blasi F, Boersma WG, Crichton ML, De Soyza A, Dimakou KE, Elborn SJ, Feldman C, Tiddens H, Haworth CS, Hill AT, Loebinger MR, Martinez-Garcia MA, Meerburg JJ, Menendez R, Morgan LC, Murris MS, Polverino E,Ringshausen FC, Shteinberg M, Sverzellati N, Tino G, Torres A, Vandendriessche T, Vendrell M, Welte T, Wilson R, Wong CA, Chalmers JD. Aliberti S, et al. Among authors:ringshausen fc. Lancet Respir Med. 2022 Mar;10(3):298-306. doi: 10.1016/S2213-2600(21)00277-0. Epub 2021 Sep 24. Lancet Respir Med. 2022. PMID:34570994 Review.
[Nontuberculous mycobacterial pulmonary disease].
Ringshausen FC, Rademacher J. Ringshausen FC, et al. Internist (Berl). 2016 Feb;57(2):142-52. doi: 10.1007/s00108-015-0014-6. Internist (Berl). 2016. PMID:26810111 Review. German.
85results